Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Nature|October 28, 2016
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironmentsEdwin D Hawkins, Delfim Duarte, Olufolake Akinduro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2025
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled TrialMichelle K Yong, Karin Thursky, Megan Crane, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
Nature Communications|May 29, 2021
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacyLauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Epigenomics|December 19, 2015
Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasmsNicole Wong Doo, Enes Makalic, JiHoon E Joo, et al.
Journal of Patient-Reported Outcomes|March 13, 2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Nature|October 28, 2016
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironmentsEdwin D Hawkins, Delfim Duarte, Olufolake Akinduro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2025
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled TrialMichelle K Yong, Karin Thursky, Megan Crane, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
Nature Communications|May 29, 2021
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacyLauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Epigenomics|December 19, 2015
Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasmsNicole Wong Doo, Enes Makalic, JiHoon E Joo, et al.
Journal of Patient-Reported Outcomes|March 13, 2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Pageof 16